Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Omeros Corp. (OMER) Announces Presentation Of Additional OMS302 Clinical Data At The Annual ASCRS And ASOA Symposium And Congress

|Includes: Omeros Corporation (OMER)

Friday, clinical-stage biopharmaceutical company Omeros announced it will present additional data from recent clinical trials of OMS302, its ophthalmology project, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium Congress, taking place April 19-23 in San Francisco.

The company's podium presentation, "Effect of an Anti-Inflammatory-Mydriatic Agent on the Incidence of Intraoperative Miosis During IOL Replacement Surgery," will summarize key analyses of Phase 2 and Phase 3 clinical data assessing OMS302's ability to reduce the incidence of miosis (pupil constricting) during intraoperative lens replacement surgery. These analyses will be included in both the company's U.S. and European marketing applications for OMS302. The data will be presented by Omeros Vice President of Clinical Development and Chief Medical Officer Steve Whitaker, M.D. on April 21 at 3:27 p.m. PDT in the Intraocular Surgery/Medications Session.

Being developed for use during intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange, OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. OMS302 is added to standard irrigation solution used in ILR procedures and delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to prevent surgically induced miosis (pupil constriction) and to reduce postoperative pain and irritation. Maintaining mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases injury risk to intraocular structures and can greatly prolong surgical time.

Recently, Omeros completed its successful OMS302 Phase 3 clinical program and plans to submit a New Drug Application to the FDA this quarter, as well as a Marketing Authorization Application to the European Medicines Agency in mid-2013.

For more information, visit www.omeros.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html